Highlights
1. Prospective observational data confirms that the risk of HBV reactivation is comparable between HCC patients with low (≤ 500 IU/ml) and high (> 500 IU/ml) baseline HBV DNA loads when receiving concurrent antiviral prophylaxis.
2. The study reported HBV reactivation rates of 4.5% in the low-load group and 6.1% in the high-load group, with no statistically significant difference (p = 0.29).
